Scientists have discovered a small genetic deletion that dramatically reduces Alzheimer’s disease risk in African Americans who carry the strongest genetic risk factor for the disease.
The finding, published in Nature Communications, identifies a 19 base pair deletion near the APOE gene that appears in 60% of African Americans with two copies of the APOE ε4 gene variant.
This variant usually increases Alzheimer’s risk by up to 12 times, but this tiny deletion seems to offer significant protection.
The deletion sits in a regulatory region that controls how much APOE protein gets made in brain cells called microglia.
When this 19 base pair sequence is missing, it blocks a transcription factor called SPI1 from binding to the DNA.
Without SPI1 repression, APOE expression patterns shift in ways that appear protective against dementia.
People with the deletion show reduced Alzheimer’s odds compared to those without it, even when they carry the high risk APOE ε4/ε4 genotype.
The deletion also delays disease onset in those who do develop Alzheimer’s.
Why This Matters Beyond One Population
APOE ε4 is the strongest and most common genetic risk factor for late onset Alzheimer’s disease, affecting more than half of all cases worldwide.
For decades, researchers have known that APOE ε4 carriers of African ancestry face lower Alzheimer’s risk than European ancestry carriers with the same genetic variant.
This phenomenon has been called the “African ancestry protective effect,” but the biological mechanism remained mysterious.
The new study finally explains a major piece of this puzzle.
By analyzing phased APOE alleles from nearly 50,000 samples in the Alzheimer’s Disease Sequencing Project, researchers pinpointed this specific deletion as a key protective factor.
Confirmation came from the All of Us research program, which validated the protective association in an independent dataset.
Here’s What Most People Get Wrong About Genetic Risk
When you hear that someone carries a “high risk” genetic variant, it’s natural to think their fate is sealed.
But genetics rarely works that simply.
This discovery challenges the notion that having APOE ε4 genes means inevitable cognitive decline.
The reality is far more nuanced.
Genetic risk exists within a complex regulatory landscape where tiny modifications can dramatically alter outcomes.
The 19 base pair deletion demonstrates how small changes in gene regulation, not just the genes themselves, shape disease susceptibility.
Think of APOE ε4 as a volume dial rather than an on/off switch.
The deletion found in African Americans effectively turns down that volume, reducing the harmful effects of the risk variant.
This regulatory protection occurs through a mechanism involving SPI1, a transcription factor crucial for microglial function.
Microglia are the brain’s immune cells, and their activity plays a central role in Alzheimer’s pathology.
When SPI1 can’t bind properly due to the deletion, it changes how these cells respond to amyloid plaques and inflammation.
The Microglial Connection
Microglia occupy center stage in this story.
These specialized brain cells normally clear cellular debris, support neurons, and respond to injury or disease.
In Alzheimer’s disease, microglia become activated and cluster around amyloid plaques.
APOE is one of the genes most strongly upregulated when microglia encounter amyloid beta, the protein that forms plaques in Alzheimer’s brains.
According to recent research on APOE in Alzheimer’s disease, the different APOE isoforms create distinct transcriptomic and epigenomic landscapes in microglia.
APOE4 appears to impair microglial proliferation, migration, and immune responses compared to the protective APOE2 variant.
The 19 base pair deletion sits approximately 1.1 kilobases downstream from the APOE gene’s 3′ untranslated region.
This location places it squarely within an enhancer region that influences gene expression.
Enhancers are DNA sequences that increase the likelihood a gene will be transcribed into protein.
When the deletion removes this particular 19 base pair sequence, it eliminates a binding site for SPI1.
SPI1, also known as PU.1, is essential for the development and function of cells in the immune system, including microglia.
Functional assays confirmed that the deletion abolishes SPI1 repression in this genomic region.
Without SPI1’s repressive activity, the regulatory landscape around APOE changes.
This alteration appears to reduce harmful APOE4 expression in microglia while potentially affecting nearby genes like APOC1.
Ancestry and the Genetic Landscape
The deletion’s prevalence varies dramatically by ancestry.
Among African Americans with APOE ε4/ε4 genotype, approximately 60% carry at least one copy of the deletion.
In Yoruba populations from West Africa, the frequency reaches 75%.
By contrast, only about 1% of European ancestry individuals carry this deletion.
This distribution reflects the deep evolutionary history of human populations and their distinct genetic architectures.
African populations harbor greater genetic diversity than populations that migrated out of Africa, carrying variants that arose over longer timeframes.
Some of these variants, like the 19 base pair deletion, turn out to confer protection against diseases that primarily affect older adults.
The researchers examined local ancestry patterns, recognizing that ancestry can vary across different chromosomal regions within a single individual.
Even among people who identify as African American, the proportion of African versus European ancestry fluctuates throughout the genome.
At the APOE locus specifically, individuals with African local ancestry showed different disease risk profiles than those with European local ancestry, even when controlling for overall genetic background.
Beyond APOE: A Network of Protective Variants
The study also identified additional genetic variants between APOE and a nearby gene called APOC1 that appear to separate APOE ε4’s neurological effects from its lipid related effects.
This finding is particularly intriguing because APOE’s primary function involves lipid transport.
The protein helps shuttle cholesterol and other fats throughout the body and brain.
APOE4 has been associated with both Alzheimer’s disease and cardiovascular conditions related to cholesterol metabolism.
The newly identified variants seem to decouple these two aspects of APOE4 biology.
Some variants affect Alzheimer’s risk without significantly impacting lipid profiles, while others do the opposite.
This disentanglement suggests that therapeutic approaches might be able to target the harmful neurological effects of APOE4 while preserving beneficial or neutral functions related to lipid metabolism.
According to recent reviews on APOE targeted therapeutics, researchers are actively developing multiple strategies to address APOE4 in Alzheimer’s disease.
These approaches include structure correctors that restore normal protein folding, agents that enhance lipidation and receptor mediated lipid transport, and methods to modulate inflammatory responses.
Gene therapies aimed at isoform switching or allele silencing represent another frontier.
The 19 base pair deletion offers a natural template for some of these therapeutic concepts.
Rather than completely eliminating APOE4 expression, the deletion modulates it in specific cell types and contexts.
This selective regulation might be safer and more effective than broad reduction of APOE levels throughout the brain.
The Broader Implications for Precision Medicine
This discovery highlights why studying genetic diversity across populations matters profoundly for medicine.
For too long, biomedical research focused primarily on people of European ancestry, missing crucial insights that emerge only when examining other populations.
African ancestry populations provide unique opportunities to understand disease because of their greater genetic diversity.
Variants that are rare or absent in European populations may be common in African populations, allowing researchers to observe their effects at meaningful frequencies.
The 19 base pair deletion exemplifies this principle perfectly.
Had researchers studied only European ancestry cohorts, this protective variant would have remained invisible due to its extreme rarity in those populations.
The findings also emphasize that genetic risk is not destiny.
Even the strongest known genetic risk factor for Alzheimer’s disease can be substantially modified by other genetic variants.
This challenges deterministic views of genetic testing and suggests that simple risk predictions based on single variants like APOE status tell an incomplete story.
Clinical and Research Implications
Understanding this protective mechanism opens several research directions.
First, it provides a natural experiment in human genetics that can guide therapeutic development.
If blocking SPI1 repression in the APOE regulatory region reduces Alzheimer’s risk, perhaps therapies could mimic this effect.
Second, the discovery refines risk prediction models.
Current algorithms for estimating Alzheimer’s risk based on APOE genotype may need adjustment for individuals of African ancestry.
Simply knowing someone carries APOE ε4/ε4 doesn’t provide the full picture without also assessing whether they have the protective deletion.
Third, the findings reinforce the importance of including diverse populations in clinical trials.
Alzheimer’s treatments may work differently depending on genetic background, including regulatory variants like this deletion.
According to the 2025 NIH Alzheimer’s Disease and Related Dementias Research Progress Report, some treatments show effects in people without APOE4 while having minimal impact in carriers of the risk gene.
This underscores the need for precision medicine approaches that account for genetic heterogeneity.
The 19 base pair deletion adds another layer to this complexity, suggesting that among APOE4 carriers, outcomes may vary based on regulatory variants.
The SPI1 Story Continues
SPI1 itself has emerged as an important player in Alzheimer’s disease beyond its role in this deletion.
The gene falls within a genome wide association study locus for Alzheimer’s, and variants that lower SPI1 expression appear protective.
This seems counterintuitive given that SPI1 is essential for microglial development and function.
How can reducing expression of a gene crucial for brain immune cells protect against a disease where immune dysfunction plays a major role?
The answer likely lies in the timing and context of SPI1 activity.
Microglia need SPI1 to develop properly, but excessive or prolonged SPI1 activity in mature microglia might drive harmful inflammatory responses.
According to research on microglial phagocytosis in Alzheimer’s disease, age reduces microglial ability to clear amyloid plaques while increasing their tendency to engulf synapses and neurons.
This dysregulation of microglial phagocytosis contributes to neurodegeneration.
SPI1 influences which genes microglia turn on in response to amyloid, affecting their inflammatory state and phagocytic activity.
The 19 base pair deletion may fine tune this response, preventing excessive inflammation while preserving beneficial microglial functions.
What This Means for Drug Development
Pharmaceutical companies have increasingly focused on APOE as a therapeutic target.
The consensus among researchers, formalized in a 2024 report from the APOE4 National Institute on Aging working group, is that reducing APOE4 levels represents a valid therapeutic goal.
However, completely eliminating APOE carries risks since the protein serves important functions in brain lipid metabolism and neuronal health.
The 19 base pair deletion suggests a more nuanced approach: modulating APOE expression in specific cell types and contexts rather than wholesale reduction.
Therapies might target the regulatory mechanisms that control when and where APOE gets expressed, particularly in microglia responding to amyloid plaques.
Gene editing technologies like CRISPR could theoretically introduce the protective deletion in people who lack it, though such approaches face significant technical and ethical hurdles.
More immediately feasible might be drugs that mimic the deletion’s regulatory effects by interfering with SPI1 binding or altering enhancer activity through epigenetic modifications.
Outstanding Questions
Despite these insights, many questions remain unanswered.
How exactly does altered SPI1 activity at this enhancer translate into changed APOE expression patterns?
What other genes besides APOE and APOC1 are affected by the deletion?
Does the deletion influence other aspects of brain aging beyond Alzheimer’s disease?
The study analyzed brain samples and found differences in gene expression associated with the deletion, but more work is needed to fully map its functional consequences.
Single cell and single nucleus sequencing studies could reveal precisely which cell types show altered gene expression and how this affects their function in Alzheimer’s pathology.
Another key question involves interactions with other genetic and environmental risk factors.
Does the deletion provide equal protection across different stages of Alzheimer’s pathology?
Does its effect vary depending on other risk genes, cardiovascular health, education level, or other modifying factors?
Toward More Inclusive Research
This discovery underscores an urgent need for more inclusive biomedical research.
For decades, genomic studies overwhelmingly focused on populations of European ancestry, creating knowledge gaps and potentially exacerbating health disparities.
When genetic risk algorithms are developed primarily in one population, they often perform poorly in others.
According to research on improving genetic risk modeling in underrepresented populations, current polygenic risk scores may exacerbate health disparities if applied without proper validation across ancestries.
The protective deletion found in African Americans illustrates why studying diverse populations benefits everyone.
Understanding this mechanism could lead to therapies applicable across all ancestries, not just those where the deletion is common.
Moreover, there are likely similar ancestry specific variants in other populations that remain undiscovered due to limited research attention.
Asian, Latino, Indigenous, and other populations each harbor unique genetic architectures that could reveal different pieces of the Alzheimer’s puzzle.
The Path Forward
The identification of this 19 base pair deletion represents both an ending and a beginning.
It solves a longstanding mystery about why African ancestry appears protective in APOE ε4 carriers.
But it also opens new avenues for research and raises fresh questions about gene regulation, microglial function, and therapeutic targeting.
In the near term, this finding should influence how doctors and genetic counselors interpret APOE testing results, particularly for individuals of African descent.
Carrying APOE ε4 variants doesn’t confer identical risk across all genetic backgrounds.
For research, the discovery provides a roadmap for investigating regulatory variants in other populations and their potential protective or risk enhancing effects.
It also offers a biological hypothesis to test in animal models and cellular systems, potentially accelerating drug development.
Perhaps most importantly, this work demonstrates the scientific and medical value of studying human genetic diversity.
Every population carries variants shaped by unique evolutionary pressures and demographic histories.
Some of these variants, like the 19 base pair deletion near APOE, can illuminate disease mechanisms and point toward new treatments.
The more we study the full spectrum of human genetic variation, the better equipped we’ll be to prevent and treat Alzheimer’s disease in all its manifestations across all populations.
A Small Deletion, A Big Lesson
Just 19 base pairs.
In the grand scheme of the three billion base pairs that make up the human genome, this deletion is microscopic.
Yet its impact on Alzheimer’s disease risk appears substantial, potentially affecting millions of people.
This reminds us that biology operates across scales, from molecular to organismal, and that small changes in regulatory sequences can have outsized effects on health and disease.
The discovery also teaches us humility about what we think we know.
For years, APOE ε4 was discussed as a straightforward risk factor, with less attention paid to why that risk varied across populations.
Now we understand that a tiny deletion, invisible in most genetic studies, explains a significant portion of that variation.
How many other protective or risk variants remain hidden in populations that haven’t been adequately studied?
As research continues, this 19 base pair deletion will likely become a focus of intense investigation, functional characterization, and perhaps therapeutic development.
It represents a victory for inclusive science and a reminder that human genetic diversity is not just interesting but medically essential.
Every variant, every population, every ancestry contributes unique insights that can advance our collective understanding of health and disease.
